Enfortumab Vedotin (Padcev)
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Enfortumab Vedotin (Padcev), covering 2025-08-29 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]